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Abstract
Introduction Guidelines on how to adjust activity in pa-
tients with a history of liver surgery who are undergo-
ing yttrium-90 radioembolisation (90Y-RE) are lacking.
The aim was to study the variability in activity prescrip-
tion in these patients, between centres with extensive
experience using resin microspheres 90Y-RE, and to
draw recommendations on activity prescription based
on an expert consensus.
Methods The variability in activity prescription between
centres was investigated by a survey of international
experts in the field of 90Y-RE. Six representative post-
surgical patients (i.e. comparable activity prescription,
different outcome) were selected. Information on pa-
tients’ disease characteristics and data needed for activ-
ity calculation was presented to the expert panel.
Reported was the used method for activity prescription
and whether, how and why activity reduction was found
indicated.
Results Ten experts took part in the survey. Recommendations
on activity reduction were highly variable between the
expert panel. The median intra-patient range was 44 Gy
(range 18–55 Gy). Reductions in prescribed activity
were recommended in 68% of the cases. In consensus,
a maximum DTarget of 50 Gy was recommended.
Conclusion With a current lack of guidelines, large variability
in activity prescription in post-surgical patients undergoing
90Y-RE exists. In consensus, DTarget ≤50 Gy is recommended.
Key points
• BSA method does not account for a decreased remnant liver
volume after surgery.
• In post-surgical patients, a volume-based activity determi-
nation method is recommended.
• In post-surgical patients, a mean DTarget of ≤ 50Gy should be
aimed for.
Keywords Dosimetry . Radioembolisation . Liver .
Guidelines . Yttrium
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Introduction
Liver surgery is often the preferred treatment option for pa-
tients with primary or secondary liver malignancies [1].
Unfortunately, primary curative liver resection is only feasible
in a small minority of patients [1], and intrahepatic recurrence
is commonly seen during follow-up [2]. When not amenable
for repeated liver surgery, patients are often directed towards
palliative therapies.
Hepatic 90Y radioembolisation (RE) with resin micro-
spheres (SIR-Spheres®, Sirtex, Sydney, Australia) is an
established treatment modality for both primary and second-
ary liver malignancies, and is considered to be safe and effec-
tive in patients with non-resectable hepatic malignancies [3].
Activity calculation [in Becquerel (Bq)] for 90Y-RE is im-
portant for accurate treatment, in terms of an effective
absorbed dose [in Gray (Gy)] to the tumour, while confirming
a safe absorbed dose to the healthy liver tissue [3]. Ideally,
activity calculation should be based on accurate and predictive
pre-treatment dosimetry [4]. However, when using 90Y resin
microspheres, international guidelines have historically rec-
ommended the simple and semi-empirical body surface area
(BSA) method for activity prescription [5–7].
Although the BSA method is popular due to its simplicity
and is generally safe within the context of its original design
[6], serious limitations for personalised dosimetry have come
to light [8, 9]. Studies have shown that BSA does not correlate
well to the liver volume or tumour dosimetry, especially in
situations of very high and very low tumour burden [9, 10].
Logically, the lack of correlation between BSA and liver vol-
ume results in even higher ambiguity in patients with a history
of liver surgery because of the reduced remnant liver volume
(RLV) [11, 12]. This scenario represents a significant number
of patients currently receiving 90Y-RE [13–15], potentially
leading to overdosing. In order to minimise the risk of clini-
cally significant radioembolisation-induced liver disease
(REILD), empirical dose reduction has been recommended
for cases of small RLV [16]. Nevertheless, guidelines on
how to adjust the prescribed activity in patients with a history
of liver surgery are currently lacking.
The primary aim of this study was to study the variability in
activity prescription in patients with a history of liver surgery
between centres with extensive experience using resin micro-
spheres 90Y-RE, and to draw recommendations on activity
prescription based on an expert panel survey.
Materials and methods
For this study, the patients’ data was retrospectively collected.
The study was reviewed by the institutional review board, and
the requirement to obtain informed consent was waived.
Records of patients undergoing 90Y-RE with resin
microspheres between February 2009 and July 2015 were
screened and patients with a history of liver surgery were
selected.
Expert panel
For the survey on current clinical practice, a selection was
made of post-surgical patients, based on their clinical history
and post-treatment outcome. The selected patients presented a
homogenous group in terms of primary malignancy and ap-
proximately comparable prescribed activity, but different sur-
gical history and post-treatment outcome in terms of toxicity.
The main goal of this selection was to reach sufficient patient
variability in terms of remnant liver volumes and treatment
outcome, in order to detect whether, how and why activity
reduction was applied. All cases were presented to 10 interna-
tional experts in the field of 90Y RE, including 9 high-volume
centres. The expert panel members were all internationally
recognized experts on 90Y RE. Included in the expert panel
were six (interventional) radiologists, three nuclear medicine
physicians (including the corresponding author) and one
hepatologist. Patients’ disease characteristics were summa-
rised and representative imaging (CT and 99mTc-MAA) were
provided as well as all necessary data needed for activity cal-
culation. The aim was to provide the expert panel members
with all data needed for dosimetry calculation according to the
current daily practice. They were blinded for treatment
outcome.
Endpoint
The panel was primarily asked to prescribe activity based on
expert opinion (along with an explanation of the rationale for
any activity adjustment), and was blinded to the actual activity
administration, and also to clinical outcome. The primary end-
point was the variability in prescribed activity for each case.
Procedure
All procedures were performed by experienced interventional
radiologists (with at least 5 years of experience) according to
standard recommendations [3]. The imagingworkup prior to the
90Y-RE procedure required at least contrast-enhanced multi-
phase CT or MRI, with or without fluorine-18 (18F)
fluorodeoxyglucose (18F-FDG) positron emission tomography/
computed tomography (PET/CT). Technetium-99 m macroag-
gregated albumin (99mTc-MAA) was used for simulation imag-
ing after coil embolisation of relevant hepatico-enteric vessels
during preparatory angiography. Activity calculations were per-
formed in compliance with international consensus guidelines
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and the package insert of resin microspheres [3, 7]. The pre-
scribed activity was calculated in GBq by the following equa-
tion = BSA (m2) – 0.2 +% tumour involvement/100 [7].
In case of significant hepatopulmonary shunting (>30 Gy
lung-absorbed dose), the prescribed activity was empirically
reduced using standard reference tables provided by the manu-
facturer. The net administered activity was determined by
correcting the prepared activity for residual activity in the v-
vial and tubing. Follow-up of patients consisted of evaluation
of the treatment by means of telephone consultation at 2 weeks,
clinical and laboratory examination at 4 weeks and imaging
follow-up at 3 months. All adverse events were reported and
toxicity was graded according to Common Terminology
Criteria for Adverse Events (CTCAE) version 4.03 [17].
Dosimetry
We defined ‘target-absorbed dose’ (DTarget) as the mean
absorbed dose (Gy) across the entire treated arterial territory,
regardless of the natural microsphere heterogeneity between
tumour and non-tumorous tissue. DTarget was retrospectively
calculated using the medical internal radiation dose (MIRD)
formula [18]. CT imaging was used to calculate the target
volume, which was converted to mass (M in kg) using an
assumed soft-tissue density of 1.06 g/ml. Homogeneous dis-
tribution of the microspheres in the target volume (including
tumour and liver parenchyma) was assumed for calculating
the DTarget utilising the following equation:
DTarget Gyð Þ ¼ AY90 GBqð Þ = M kgð Þ½ *50 J=GBqð Þ;
where AY90 is the administered activity corrected for lung shunt.
Statistical analysis
Descriptive analyses were performed to summarize patient
demographics and treatment characteristics. The variability
in prescribed activity in each case was illustrated graphically.
The variability was quantified by reporting the range of pre-
scribed activity for each case and comparing it with the BSA-
based prescribed activity. A commercial statistical software
package (SPSS for Windows, version 19.0; SPSS Inc,
Chicago, IL, USA) was used for data analysis.
Results
Patient population
Between February 2009 and July 2015, 187 consecutive pa-
tients with primary and secondary liver malignancies
underwent 90Y-RE with resin microspheres in our clinic.
Forty-three patients had a history of liver surgery varying
from ablative therapy to an extended hemihepatectomy.
Six patients were found eligible for the expert panel sur-
vey (Table 1). Five out of the six patients received 90Y-RE
for colorectal liver metastases and one patient received
treatment for cholangiocarcinoma. In all patients, the entire
remnant liver was treated. The data used for activity cal-
culation and presented to the expert panel is presented in
Table 2.
For comparison between cases and experts, all prescribed
activities were reported as target-absorbed dose or DTarget,
using prescribed activities and target volumes as described
above. The actual prescribed activity ranged from 1.74 to
2.07 GBq and resulted in a DTarget of 42–76 Gy. In three out
of six patients (cases 3, 4 and 6), the delivered activity was
reduced due to previous liver resection. The lowest net deliv-
eredDTarget was 40Gy in case 2 with RLVof 2306mL, and the
largest net delivered DTarget was 54Gy in case 6, with a RLVof
1091 mL (Table 2).
Expert review and correlation
The recommended activity adjustment for individual patients
was highly variable and there was no consensus for any of the
cases (Figure 1). The median intra-patient range (i.e. the
highest minus the lowest recommended DTarget) was 44 Gy
(range 18–55 Gy). Reductions were reported 41 out of 60
times (68%), no treatment at all in 2 out of 60 times
(3%), and there was one missing in the survey (2%;
Table 3). Different methods were used to calculate the
prescribed activity in cases of reduction. For most reduc-
tions (17/41; 41%), the experts chose to empirically reduce
the activity as a percentage of the prescribed activity
based on the BSA method (median 20%, range 10–
60%). In other cases (15/41; 37%) a pre-set maximum
safe DTarget was recommended (median 50 Gy, range 35–
55 Gy).The partition model was recommended 3 out of 41
times (7%). In these cases, the recommended Dtumour,
DLung and maximum dose on healthy liver were given
(median 40 Gy, range 40–54 Gy). Finally, in 6 out of
41 reductions (15%), an empirically prescribed activity
was recommended (median 46 Gy, range 34–58 Gy;
Table 3). Repeatedly, >1 reason for dose reduction was
mentioned, resulting in a total of 65 reported reasons.
Small RLV was the most frequent reason for activity re-
duction (24/65; 37%). Other arguments for reduction were:
previous systemic therapy (16/65; 24%), low tumour bur-
den (10/65; 15%), findings of unfavourable microsphere
biodistribution on 99mTc-MAA SPECT (8/65; 12%), al-
tered liver function (5/65; 8%), previous radiotherapy
(1/65; 2%), and performance status (1/65; 2%).
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Toxicity and outcome
Post-treatment clinical symptoms were generally minor and
included transient nausea, pain and fatigue related to the post-
embolisation syndrome (Table 4). REILD was seen in one pa-
tient (case 6) who developed grade 3 ascites with elevated liver
biochemistry tests (with grade 1 hyperbilirubinemia at last mea-
surement) and died 71 days after the treatment. The remaining
cases developed only mild clinical and laboratory symptoms.
With regards to disease outcome, case 2 was the first to develop
progressive disease (within 3 months) and died 10 days after
treatment due to progressive disease. Notably, the patient who
developed REILD (case 6) had the smallest RLVand received
the highest net DTarget, while the latter patient (case 2) had the
largest RLVand received the smallest DTarget. The
99mTc-MAA
SPECT images and the pre-procedural CT imaging of these two
cases are shown in Figure 2.
Discussion
In general, 90Y-RE resin microspheres are safe for most pa-
tients with a history of liver surgery. However, the currently
advocated BSA method for activity calculation does not in-
corporate the actual liver volume. In patients with extensive
liver surgery, the remnant liver volume may have been signif-
icantly reduced, leading to potential overdosing in case this is
not accounted for. Remarkably, there have been no publica-
tions on the effects of dosimetry on the outcome in terms of
treatment response and toxicity in post-surgical patients. Since
guidelines are lacking, the variability in used methods to re-
duce activity may be large. Consequently, administration of
excessive activities to the normal liver parenchyma in post-
surgical patients does occur, leading to fatal REILD in some
cases. This study demonstrated that in current clinical practice,
there is no consensus regarding the preferred method of ad-
justment of the prescribed activity in patients with a history of
liver surgery. These findings raise some safety concerns for
90Y-RE after liver surgery.
Only a few studies have investigated the safety of 90Y-RE
resin microspheres in patients with a history of liver surgery
[13–15]. In all of these studies, activity calculation was based
on the BSA method. It was, therefore, suggested that this
method can safely be used in post-surgical patients.
However, controversy remains, as it has been shown that the
BSA model does not correlate well with liver volume, specif-
ically in large and/or obese patients [8, 9]. Furthermore, pa-
tients that have undergone hepatic surgery pose an even great-
er challenge due to altered liver volume secondary to regen-
eration [9, 10], and due to a reduced liver functional reserve
that may result in an increased risk of REILD. Significantly
higher activity concentrations in the normal liver parenchyma
can be measured in patients with pre-existent smaller liverTa
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Fig. 1 The target absorbed dose
(Gy) as recommended by the
expert panel for each case (A–F).
The median (and range)
recommended absorbed dose for
each case was 49Gy, range 32–54
(A), 42 Gy, range 0–55 Gy (B),
55 Gy, range 30–76 Gy (C),
53 Gy, range 50–68 Gy (D),
46 Gy, range 0–50 Gy (E) and
59 Gy, range 35–76 Gy (F). Note:
0 Gy means that the expert
advised not to treat that specific
patient at all.
Table 2 Data of patients selected for the expert panel that was used for activity calculation based on the BSA method
Case BSA (m2) Target
volume (mL)
tumour
burden (%)
Lung
shunt (%)
Activity based on
BSA (GBq)
Target dose based
on BSA (Gy)
Target dose in case
of reduction (Gy)#
Net delivered
dose (Gy)*
1 2.06 1654 3 8 1.89 54 - 47
2 2.17 2306 10 1 2.07 42 - 40
3 1.91 1091 5 3 1.76 76 50 44
4 1.79 1218 15 5 1.74 70 50 43
5 2.05 1894 6 4 1.91 48 - 45
6 1.90 1091 6 4 1.76 76 57 54
# The net target absorbed dose that was delivered after reduction: 50 Gy target absorbed dose in case 3 and 4, 25% reduction in case 6.
* The net delivered target absorbed dose is the mean absorbed dose (Gy) across the entire treated arterial territory calculated by the net administered
activity.
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volumes, or reduced liver volumes [10]. The cases of the
expert panel survey showed significant toxicity in case of a
high DTarget (Gy) in a patient with a relatively small RLV (i.e.
overdosing), and suggested underdosing in case of a small
DTarget (Gy) in patients with a relatively large RLV (and com-
parable BSA). This finding again illustrates the lack of corre-
lation between BSA and the (remnant) liver volume.
The results of the survey illustrated the lack of consensus
regarding the preferred method of activity reduction in any of
the cases. Moreover, different methods were used for activity
adjustment. In a high percentage of cases, the expert panel agreed
on the fact that a low RLV is an argument for careful use of the
BSA method, due to the high risk of an overdose. Preferably, a
specific DTarget was prescribed (frequently ±50 Gy), and in some
Table 3 The prescribed DTarget
(Gy) for each case as advised by
the expert panel
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Expert 1 Type
DTarget (Gy)
PC
49
PC
39
PC
68
PC
63
No treatment PC
68
Expert 2 Type
DTarget (Gy)
NR
54
NR
42
MIRD
50
MIRD
50
PC
38
MIRD
50
Expert 3 Type
DTarget (Gy)
PC
32
PC
21
PC
30
Missing PC
38
PC
30
Expert 4 Type
DTarget (Gy)
PM
40
No
Treatment
MIRD
35
PM
54
PM
40
MIRD
35
Expert 5 Type
DTarget (Gy)
EPA
40
EPA
34
EPA
58
EPA
54
EPA
37
EPA
52
Expert 6 Type
DTarget (Gy)
NR
54
NR
42
NR
76
NR
70
PC
34
NR
76
Expert 7 Type
DTarget (Gy)
PC
43
NR
42
PC
61
PC
56
NR
48
NR
76
Expert 8 Type
DTarget (Gy)
NR
54
NR
42
MIRD
50-60
MIRD
50-60
NR
48
PC
60
Expert 9 Type
DTarget (Gy)
MIRD
45
MIRD
55
MIRD
45
MIRD
55
MIRD
50
MIRD
40
Expert 10 Type
DTarget (Gy)
NR
54
NR
42
MIRD
50
MIRD
50
NR
48
PC
57
EPA Empirically prescribed activity,MIRDMaximum safe whole liver absorbed dose (DTarget) based on Medical
Internal Radiation Dose (MIRD) dosimetry, NR no reduction was recommended, PC Empirical reduction of the
activity as a percentage of the prescribed activity based on the BSA method, PM Partition model with prescribed
DTumour, DHL and DLung (the tumour to non-tumour ratio was assumed).
Table 4 Reported adverse events
within 3 months following the
90Y RE procedure according to
the CTCAE version 4.03 for the
six cases presented to the expert
panel
Adverse
events
Laboratory toxicity* Clinical toxicity
Case 1 ALP (+1 CTC) GGT (+3 CTC) ASAT (+1 CTC)
ALAT (+1 CTC)
Fatigue (CTC 1) Nausea (CTC 1)
Case 2 ALP (+1 CTC) GGT (+1 CTC) Fatigue (CTC 2) Nausea (CTC 1) Pain
(CTC 2)
Case 3 Bili (+2 CTC) ALP (+1 CTC) ASAT (+1 CTC) Fatigue (CTC 1) Nausea (CTC 1) Pain
(CTC 1)
Case 4 GGT (+1 CTC) ASAT (+1 CTC) ALAT (+1 CTC) None
Case 5 Bili (+1 CTC) Fatigue (CTC 1) Pain (CTC 1)
Jaundice
Case 6 Bili (+1 CTC) ALP (+1 CTC) ALAT (+1 CTC)
Albumin (+2 CTC)
Pain (CTC 2) Ascites (CTC 2)
ALAT alanine transaminase, ALP alkaline phosphatase, ASAT aspartate aminotransferase; Bili: bilirubin, CTC
common toxicity criteria, GGT gamma-glutamyl transferase.
*Laboratory toxicity is reported as highest increase in CTC toxicity grade compared to baseline CTC
grade (+1 etc.)
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cases, the DTarget was further specified in terms of absorbed dose
to the tumour tissue, non-tumour tissue and the lungs, according
to the ‘partition model’ which is based on MIRD
macrodosimetry [6, 18, 19]. Clinical explanations may be pro-
vided for the differences in activity prescription provided by the
expert panel. The patients who are eligible for 90Y-RE treatment
represent a heterogeneous group with distinct disease charac-
teristics. There is significant diversity in the patients’ medical
histories, such as prior chemotherapy, which is known to
increase the risk of REILD [20]. Also, tumour vascularity
may differ, which influences the microsphere biodistribution
of the delivered activity to tumour and non-tumour tissue [8].
It has been mentioned previously that the BSA method ne-
glects the inter-patient variability in tumour-to-normal liver
tissue microsphere biodistribution [6, 19], a possible argu-
ment for activity adjustment. Lastly, the extent of liver sur-
gery differs highly, resulting in large differences between
remnant liver volumes.
A limitation of this study is the retrospective selection of
patients in the survey. However, the selected patients were
representative for daily practice, with risk of under- and
overdosing in patients with similar prescribed activity (based
on the BSAmethod) but distinct RLVand DTarget. Hence, the
lack of guidelines for dosimetry, especially in this patient
group, directly affects clinical outcome and should be inves-
tigated more thoroughly.
Based on these results, the blind application of the BSA
method for activity prescription in patients with previous liver
surgery is discouraged. Based on the reports of the expert
panel, the following consensus recommendation can be made;
for activity calculation of 90Y-RE using resin microspheres, a
volume-based activity calculation algorithm is recommended,
such as the MIRD method that takes RLV into account. A
maximum DTarget of 50 Gy seems a safe interim recommenda-
tion, with further reduction in the case of relatively
hypovascular tumours, dismal baseline liver function, or a
heavily pre-treated patient. The partition model may also war-
rant further consideration and research as it theoretically takes
into account the differential activity biodistribution to both the
tumour and the normal liver tissue [19, 21]. As regards to a
recommended safe cut-off value for the dose on healthy liver
tissue, different possible safe cut-off points have been reported
[6, 22]. However, in view of the applicability of the partition
model for individualised dosimetry, more research on this topic
is essential. Finally, in order to facilitate patient-specific dosim-
etry of 90Y-RE treatment and future research on this topic, ac-
cessible tools have been developed [23].
Conclusion
Caution should be taken when using the BSA method for
activity prescription in patients with previous liver resection.
Based on the survey of the expert panel, an interim recom-
mendation is to use a volume-based activity determination
method such as the MIRD-based model instead, aiming for a
mean absorbed dose across the target arterial territory (DTarget)
Fig. 2 The 99mTc-MAA SPECT
(A and C) and the pre-procedural
CT imaging (B and D) of,
respectively, cases 2 and 6 as
presented to the expert panel
along with following information:
the 99mTc-MAA SPECT of case 2
shows low activity around the
largest lesion in segment VIII and
relatively high uptake in the
healthy liver parenchyma after
injection of MAA in the left
hepatic artery (A and B). In case
6, the 99mTc-MAA SPECT and
the pre-procedural CT imaging
show distribution of the activity
throughout the remnant liver,
although with lack of activity
uptake around the largest
lesion as depicted by the red
circle (C and D).
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of ≤50Gy, until the emergence ofmore robust dosimetric data.
Partition modelling should lead to further refinement in per-
sonalised activity calculation based on healthy liver and lung-
absorbed dose thresholds.
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